Indian Journal of Hematology and Blood Transfusion
Latest Publications


TOTAL DOCUMENTS

1569
(FIVE YEARS 449)

H-INDEX

14
(FIVE YEARS 4)

Published By Springer-Verlag

0974-0449, 0971-4502

Author(s):  
Tejasvini Vaid ◽  
Mukul Aggarwal ◽  
Akriti Khare ◽  
Ganesh Kumar Viswanathan ◽  
Jasmita Dass ◽  
...  

Author(s):  
Karthik Srevatsa ◽  
Garima Jain ◽  
Deepam Pushpam ◽  
Aparna Ningombam ◽  
Anita Chopra

Author(s):  
Marcial Álvarez-Salafranca ◽  
Pablo Villagrasa-Boli ◽  
Sara Martínez-Cisneros ◽  
Mar García-García
Keyword(s):  

Author(s):  
Katarzyna Duda ◽  
Agata Wieczorkiewicz-Kabut ◽  
Adrianna Spałek ◽  
Anna Koclęga ◽  
Anna J. Kopińska ◽  
...  

AbstractAllogeneic stem cell transplantation (allo-SCT) remains the only curative therapeutic approach for patients with myelodysplastic syndromes (MDS). The aim of the study was to assess the efficacy/safety of allo-SCT as well as to identify factors influencing post-transplant survival. One hundred and two MDS patients (median age: 48 years; 57 males) who underwent allo-SCT were retrospectively evaluated. Twenty seven patients were transplanted from HLA-matched sibling and 75 patients received grafts from unrelated donors. Peripheral blood was a source of stem cell for 79 patients. Reduced intensity conditioning was used in 64 subjects. Acute and chronic graft versus host disease (GvHD) developed in 61 and 19 of patients, respectively. In total, 61 patients have died. The causes of deaths included infectious complications (n = 30), steroid-resistant GvHD (n = 17), MDS relapse (n = 9) and transformation to AML (n = 5). Non-relapse mortality and cumulative incidence of relapse at 2 years were 49.8% and 9%, respectively. 41 patients are alive at last contact and present full donor chimerism. 38 patients remain in complete hematological remission (CHR), 3 patients had CHR with incomplete platelet recovery. Median follow-up from diagnosis of MDS and transplantation are 27.1 months and 7 months respectively. Overall survival and relapse-free survival were 41% at 2 years. Increased serum ferritin level > 1000 ng/ml, presence of acute GvHD, grades III–IV acute GvHD and high hematopoietic cell transplantation-comorbidity index were found to negatively influenced survival. Allo-SCT for MDS is feasible procedure with a proportion of patients to be cured.


Author(s):  
Parmatma Prasad Tripathi ◽  
Vijay Kumawat ◽  
Gopal Kumar Patidar
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document